Highlights

  • SomnoMed (ASX:SOM) reported FY26 Revenue of A$114.5 million, up 3%, while EBITDA increased 19% to A$10.9 million.
  • EBITDA Margin expanded to 9.6% from 8.2%, despite relatively modest top-line growth.
  • The company ended FY26 with A$17.2 million in cash and A$0.4 million of debt.
  • FY27 ambitions include high single-digit revenue growth while maintaining EBITDA margins broadly consistent with FY26.

SomnoMed (ASX:SOM), the Sydney-based developer of oral devices for obstructive sleep apnoea, closed FY26 with higher revenue, improved Earnings margins and a relatively low level of debt.

For investors assessing the company's outlook, the key issue is the balance between stronger profitability and the pressures that limited revenue growth during FY26, including European reimbursement changes and currency movements. Management's FY27 growth ambitions now provide a measurable benchmark for the next phase.

Latest Development

In its full-year results released in late August 2026, SomnoMed (ASX:SOM) reported revenue of A$114.5 million for FY26, up 3% on the prior year, while EBITDA increased 19% to A$10.9 million from A$9.2 million in FY25.

Margin expansion was more pronounced than revenue growth. EBITDA margin increased to 9.6% from 8.2%, representing an improvement of approximately 140 basis points.

Alongside the result, the company outlined an FY27 ambition of high single-digit revenue growth while maintaining EBITDA margins broadly consistent with FY26 levels.

Company Overview

SomnoMed (ASX:SOM) commercialises the SomnoDent mandibular advancement splint and related oral appliances used in the treatment of obstructive sleep apnoea. These custom-fitted devices provide an alternative treatment option to continuous positive airway pressure therapy and are distributed through dental and sleep clinics.

Headquartered in Crows Nest, New South Wales, and listed on the ASX since August 2004, SomnoMed generates most of its revenue outside Australia.

For FY26, Europe contributed A$61.9 million in revenue, North America generated A$45.8 million and Asia Pacific contributed A$6.8 million.

Recent Developments

In an update released in late July 2026, SomnoMed advised that unaudited FY26 revenue was expected to be between A$114 million and A$115 million, compared with its earlier guidance range of A$119 million to A$126 million.

The company attributed the shortfall to reimbursement changes across European markets and appreciation in the Australian dollar, which it estimated reduced reported second-half growth by approximately 600 basis points.

The same update included a Leadership change. Amrita Blickstead stepped down as Co-Chief Executive Officer and Executive Director, leaving Karen Borg, who had served as Co-CEO since February 2024, as sole Chief Executive Officer. Greg Knight moved from Chief Transformation Officer to Chief Operating Officer.

SomnoMed (ASX:SOM) also launched Virtus globally, an oral appliance designed for patients experiencing sleep apnoea alongside sleep bruxism.

Financial and Operational Position

SomnoMed finished FY26 with A$17.2 million in cash, broadly unchanged from the prior period, and Debt of A$0.4 million following a 48% reduction. This left the company with net cash of approximately A$16.8 million.

Operating cash flow after Lease expenses improved to A$5.2 million from A$4.8 million, while Capital Expenditure increased to A$5.7 million from A$4.0 million.

Currency movements had a meaningful influence on reported performance. North American revenue increased 6% on a reported basis but rose 11% in constant currency. European revenue increased 1% as reported but declined 1% in constant currency.

Second-half revenue declined 7% in Australian dollar terms but fell by less than 1% on a constant-currency basis.

What Investors May Watch Next

SomnoMed's FY27 targets provide a clear benchmark. Delivering high single-digit revenue growth after FY26 growth of 3%, while maintaining EBITDA margins, would require a stronger top-line trajectory.

Other areas to monitor include the evolution of reimbursement conditions in Europe, whether North American constant-currency momentum can be sustained, early commercial traction for Virtus and whether the higher capital expenditure level continues.

Progress against these operational indicators will help determine whether the margin improvement achieved in FY26 can be accompanied by stronger revenue growth.

Risks

Europe accounted for more than half of SomnoMed's FY26 revenue, leaving the company meaningfully exposed to further changes in reimbursement conditions across the region.

Currency movements also remain relevant, with the stronger Australian dollar already weighing on reported growth during FY26.

SomnoMed (ASX:SOM) reduced its revenue guidance during FY26, which may increase scrutiny of future targets. The company also competes with continuous positive airway pressure therapy and other oral appliance providers.

Capital expenditure exceeded Operating Cash Flow after lease expenses during FY26, making future Investment requirements and cash generation additional areas to monitor.

Conclusion

SomnoMed (ASX:SOM) enters FY27 with improved EBITDA margins, a net cash position and continued exposure to international sleep-apnoea markets, but revenue growth remained below earlier expectations during FY26.

The key test ahead will be whether the company can deliver its targeted high single-digit revenue growth while preserving the margin gains achieved over the past year. European reimbursement conditions, currency movements, North American growth and adoption of newer products such as Virtus will all influence that outcome.